Loading clinical trials...
Loading clinical trials...
A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma
Conditions
Interventions
TPI 287
Temozolomide
+1 more
Locations
8
United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Rady Children's Hospital
San Diego, California, United States
Connecticut Children's Hospital
Hartford, Connecticut, United States
Arnold Palmer Hospital for Children- MD Anderson
Orlando, Florida, United States
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Start Date
December 1, 2011
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
August 6, 2024
NCT04936529
NCT06541262
NCT04851119
NCT03363373
NCT05890781
NCT03050268
Lead Sponsor
Giselle Sholler
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions